转移性黑色素瘤免疫检查点阻断治疗反应的稳健预测
本研究构建了免疫预测评分(IMPRES),基于免疫检查点基因间15对转录组关系预测黑色素瘤对免疫检查点阻断(ICB)的反应。IMPRES在9个已发表数据集及一个新生成数据集(31例抗PD-1和10例抗CTLA-4,共297个样本)中验证,总体AUC=0.83,优于现有预测器,可捕获几乎全部真反应者,同时将不到一半的非反应者误分类。
要点
- IMPRES基于15对免疫检查点基因表达关系预测ICB反应。
- 在297个样本中验证,AUC=0.83,优于现有预测器。
- 可捕获几乎全部真反应者,误分类不到一半非反应者。
核心结论
- IMPRES是黑色素瘤ICB反应的稳健预测器,在验证中AUC=0.83,优于现有预测器。
研究设计与样本
- 基于转录组数据构建预测器,并在9个已发表数据集及一个新生成数据集(31例抗PD-1和10例抗CTLA-4,共297个样本)中验证。
主要发现
- IMPRES在验证中总体AUC=0.83,优于现有预测器。
- IMPRES捕获几乎全部真反应者,同时将不到一半的非反应者误分类。
关键数值与推荐
- IMPRES涵盖免疫检查点基因间15对转录组关系。
临床怎么用
- IMPRES可用于预测黑色素瘤患者对ICB治疗的反应,辅助临床决策。
局限性
- 未来需研究该方法在其他癌症类型中的价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immune checkpoint blockade (ICB) therapy provides remarkable clinical gains and has been very successful in treatment of melanoma. However, only a subset of patients with advanced tumors currently benefit from ICB therapies, which at times incur considerable side effects and costs. Constructing predictors of patient response has remained a serious challenge because of the complexity of the immune response and the shortage of large cohorts of ICB-treated patients that include both 'omics' and response data. Here we build immuno-predictive score (IMPRES), a predictor of ICB response in melanoma which encompasses 15 pairwise transcriptomics relations between immune checkpoint genes. It is based on two key conjectures: (i) immune mechanisms underlying spontaneous regression in neuroblastoma can predict melanoma response to ICB, and (ii) key immune interactions can be captured via specific pairwise relations of the expression of immune checkpoint genes. IMPRES is validated on nine published datasets1-6 and on a newly generated dataset with 31 patients treated with anti-PD-1 and 10 with anti-CTLA-4, spanning 297 samples in total. It achieves an overall accuracy of AUC = 0.83, outperforming existing predictors and capturing almost all true responders while misclassifying less than half of the nonresponders. Future studies are warranted to determine the value of the approach presented here in other cancer types.
引用
- Auslander N, Zhang G, Lee JS, et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat Med. 2018. PMID: 30127394. doi:10.1038/s41591-018-0157-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。